Korea Mulls New Biosimilar Guidelines As Pipeline Surges
This article was originally published in PharmAsia News
As more biosimilar products are set to be released in South Korea, with a hefty number of ongoing late-stage clinical trials, the country is seeking to introduce a new separate guideline for insulin biosimilars. While South Korea has introduced biosimilar guidelines relatively earlier than some others, a local institute suggests these still need to be improved, pointing to a lack of clarity and implementation issues.
Register for our free email digests: